Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is on track to achieve significant growth in the coming years due to the successful development and commercialization of Pylarify, a PSMA imaging agent for prostate cancer, as well as a robust portfolio of precision diagnostics including DEFINITY and Neuraceq. Additionally, their Alzheimer's diagnostic pipeline, including the recently approved MK6240, has the potential to significantly increase their market share in the future. Risks to the company's outlook include pricing challenges and potential delays in securing TPT status for their products, as well as potential operational and execution shortfalls following recent leadership changes and a pending CEO transition. Overall, LNTH's strong financial performance and strategic initiatives position it as an attractive investment opportunity in the competitive field of radiopharmaceuticals.

Bears say

Lantheus Holdings is projected to have a higher 2027 EPS, but is currently trading at a lower P/E ratio compared to its peers. With a potential re-acceleration in revenue and EPS growth in 2027, the company's multiple could increase and close the gap with its peers. Additionally, the company's gross profit has remained relatively stable, with recent divestitures and product volumes offsetting a decrease in net price. However, there may be potential margin dilution in the near-term due to new manufacturing facilities and product pricing.

Lantheus Holdings (LNTH) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 7 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.